Wewards, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
Wewards, Inc. filed its Q3 2026 10-Q, revealing ongoing net losses, negative working capital, and substantial doubt about its ability to continue as a going concern.
OTC.Pink
Wewards, Inc. reported continued net losses and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
OTC.Pink
Wewards, Inc. reported a net loss of $159,009 for Q1 2026, with significant going concern doubts and continued reliance on related-party financing.
OTC.Pink
Wewards Inc. reports ongoing losses for the third quarter of 2025 as it seeks licensing agreements for its web-based platform.
OTC.Pink
Wewards Inc. reports a net loss of $299,557 for the six months ended November 30, 2024, and continues to rely on related party funding while seeking licensing agreements for its platform.
OTC.Pink
Wewards Inc. reported no revenue for the first quarter of 2025, but reduced its net loss compared to the same period last year, while still facing substantial doubt about its ability to continue as a going concern.
OTC.Pink
Wewards Inc. reports a decreased operating loss for the third quarter of 2024, primarily due to the termination of their office lease, while still facing significant financial challenges and a going concern warning.
OTC.Pink
Wewards Inc. reported a decreased operating loss for the quarter ended November 30, 2023, despite not generating any revenue, as the company continues to seek licensing agreements for its platform.